Genmab stock surges 11% on positive cancer drug trial data
Genmab shares rose 11% after the company reported positive data from a cancer drug trial. The result links clinical research news with a substantial market reaction.
Genmab cancer drug clinical trial positive trial data stock surge
Linked Entities
Contributing Articles
Genmab stock surges 11% on positive cancer drug trial data
Investing.com —